Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTCHD1 antisense RNA (head to head), abbreviated as PTCHD1-AS, is a long non-coding RNA (lncRNA) located on the X chromosome, oriented head-to-head with the PTCHD1 gene[4][5][6][7]. It does not code for protein. Genetic deletions involving PTCHD1-AS have been strongly linked to susceptibility for autism spectrum disorder (ASD) in males, particularly with deficits in social behavior and repetitive actions without intellectual disability or ADHD[1][3]. Experimental studies in human neurons and knockout mice indicate its critical role in regulating synaptic function and gene expression pathways involved in neurodevelopment, especially in GABAergic regions like the striatum[1][3]. While also known by aliases such as DDX53-AS1 and PHEX-AS1, PTCHD1-AS is not a conventional therapeutic target (such as a receptor or enzyme) and there are no drugs targeting it directly. Its precise biological function is under investigation, though it may offer insights into the molecular basis of ASD and related neurological conditions[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PTCHD1 antisense RNA (head to head) (PTCHD1-AS).